South Africa has a weight loss drug problem

Pharmaceutical manufacturers, regulators, and healthcare professionals in South Africa are urging law enforcement to take action against the sale of unregistered weight loss medications. 

The Pharmaceutical Task Group (PTG) has issued a warning that illegal medications are increasingly being sold through online platforms, including websites, social media, messaging services, wellness clinics, and other informal channels. 

This trend poses a significant risk to patients and places additional pressure on regulators, border and customs authorities, healthcare professionals, and the pharmaceutical industry. 

Daphney Fafudi, the Senior Manager for Market Control at the South African Health Products Regulatory Authority (SAHPRA), emphasised that individuals purchasing medications from informal sources should carefully consider the contents of these products.

“Patients often focus on whether a medicine works. But the real question is whether anyone knows what is in that product, whether it was manufactured correctly, whether it contains the correct ingredients, and whether it has been appropriately assessed and authorised,” said Fafudi.

Other high-demand products being sold in informal markets include codeine-containing medicines, skin-lightening products, and performance-enhancing substances. 

Fafudi noted that the scale of this issue is increasing, with authorities reporting around 600 complaints concerning illegitimate and counterfeit products sold through unauthorised channels. 

Additionally, the Border Management Authority (BMA) reported intercepting over 1.7 million suspicious pharmaceutical-related products as part of its border management protocols. 

PTG Chairperson Stavros Nicolaou informed Cape Talk that even registered medicines are being smuggled into the country by unknown sources or by suppliers that do not comply with quality standards or approvals.

“It’s a combination of things, and a growing problem which seems to have exacerbated with these GLP-1 weight loss products, which are understandably in high demand,” he said.

Nicolaou warned that the risk to patients and the public from these unregistered medicines obtained through informal channels is significant.

“Retatrutide is a medicine that is showing a lot of potential, but it is still in the experimental stage, so in other words, it’s still undergoing clinical trials to determine the quality, safety, and efficacy of the product,” he said.

Retatrutide is an experimental, once-weekly injectable medicine developed by Eli Lilly and Company to treat obesity, type 2 diabetes, and metabolic disorders.

“It’s absolutely astonishing; it’s almost egregious, I’d suggest, that before a medicine is proven or registered anywhere in the world, we are already seeing copies of that in our own country.”

A crime that goes beyond patient safety

Nicolaou has urged stakeholders and relevant authorities to treat healthcare crime as a serious issue that extends beyond patient safety.

“Healthcare crime is both a patient-safety issue and an economic-crime issue. It harms patients, weakens trust in healthcare systems, undermines legitimate businesses, discourages investment and diverts economic activity away from the formal economy,” said Nicolaou.

He stated that organised criminal networks take advantage of fragmented systems. Stronger cooperation among regulators, border and customs authorities, healthcare professionals, professional councils, government, and industry will be essential in addressing this issue.

“Criminal networks collaborate. Those protecting patients must collaborate, too,” he said.

When addressing the statistics on the counter-effects of medicines that are not yet registered, Nicolaou said that if left unaddressed, the problem will grow into a bigger one.

“When you start losing the integrity of your pharmaceutical regulatory and value chain, then you are in trouble as a country,” he said.

He emphasised that clinical trials, particularly those involving retatrutide, cannot be rushed, as doing so may compromise quality and safety outcomes. 

In his 40 years of industry experience, Nicolaou noted that the presence of unregistered medicines and those still undergoing clinical trials in the market is unprecedented. 

He pointed out that a common method for introducing unregistered products, such as certain peptides or counterfeit GLP-1 medications, into the country is through its ports, where they are often disguised as other items, such as cat food or vitamins. 

Nicolaou explained that this process typically involves individuals who are not healthcare professionals, and the products may end up in the hands of hairdressers, gym instructors, and beauty salons. 

He said that regardless of who sells unregistered medicines, whether it’s a doctor, a pharmacy, or a member of the public, it remains illegal.

You have read 1 out of 5 free articles. Log in or register for unlimited access.

  1. Lizette Walker
    18 November 2026 at 17:31

    Hahaha 😂 The government will do absolutely nothing about this.. it does not affect any of them… if poor quality weight loss medicine is making it’s way into South Africa… members of ruling party do explicitly not use them….

Which option do you prefer?

View results

Loading ... Loading ...